Liminatus Pharma, Inc. (LIMN): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$9.98M

Year ended 2025-12-31

Period ended	Free Cash Flow	Change YoY	Source filing
2025-12-31	-$9.98M	n/a	2026-03-31, From 2025-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Free Cash Flow	Change YoY
Liminatus Pharma, Inc. (LIMN)	2025-12-31	-$9.98M	n/a
Zeo ScientifiX, Inc. (ZEOX)	2025-10-31	-$741.0K	n/a
BioCardia, Inc. (BCDA)	2025-12-31	-$7.44M	n/m
Tevogen Inc. (TVGN)	2025-12-31	-$12.39M	n/a
AIM ImmunoTech Inc. (AIM)	2024-12-31	-$14.91M	n/a
Exozymes Inc. (EXOZ)	2025-12-31	-$6.67M	n/m
Silexion Therapeutics Corp (SLXN)	2025-12-31	-$10.83M	n/m
VivoSim Labs, Inc. (VIVS)	2026-03-31	-$10.83M	n/m
Scinai Immunotherapeutics Ltd. (SCNI)	2025-12-31	-$6.05M	n/m

Compare LIMN, ZEOX, BCDA, TVGN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗